Biocare Medical launches a highly specific six antibody panel for differentiation of adenocarcinoma vs. squamous cell carcinoma of the lung

Biocare Medical is proud to announce the launch of the PulmoPanel™ Multiplex IHC to clearly differentiate between adenocarcinoma (LADC) and squamous cell carcinoma (SqCC) of the lung with 97% specificity and 93% sensitivity. This Multiplex IHC contains six antibodies (TTF-1, Napsin A, p63, TRIM29, Desmoglein 3 and CK5), and aids in the critical differentiation of NSCLC squamous vs. adenocarcinoma, essential in therapeutic decisions such as the use of VEGF or EGFR inhibitors. This is especially important as patients with lung SqCC should not receive Avastin due to a 30% mortality rate by fatal pulmonary hemorrhage. Studies of 210 lung cancer cases have shown that PulmoPanel is an effective screener for discriminating between lung squamous cell carcinoma and lung adenocarcinoma. Positive staining with Napsin A and/or TTF-1 provided 91.3% sensitivity and 94.7% specificity for LADC (P < .0001). Desmoglein 3 and/or CK5 resulted in 92.6% sensitivity and 100% specificity for SqCC (P < .0001). p63 and/or TRIM29 provided 94.7% sensitivity and 89.6% specificity for SqCC, in cases where both TTF-1 and Napsin A were negative (P < .0001).

The PulmoPanel™ along with its simple interpretation provides an invaluable tool for lung carcinoma diagnosis.

To learn more about the PulmoPanel™ visit http://biocare.net/products/antibodies/p/436/

About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous Multiplex IHC and antibody development which solves difficult clinical problems and accelerates turnaround time. The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies, as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare Medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.

Leave a Reply